Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brandon Miller

Family Medicine Cincinnati, OH Doctor of Osteopathy

NPI 1124523105 CMS profile 7225525

8000 5 Mile Rd Ste 213, Cincinnati, OH 45230

Open in the dashboard

General payments

$1,153

60 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brandon Miller of Cincinnati, OH is reported in the CMS Open Payments database as having received $1,153 across 60 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $385 20
2024 General $149 8
2023 General $570 28
2022 General $12 1
2019 General $37 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brandon Miller
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Brandon Miller were reported at $385. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Brandon Miller Family Medicine median Middle half National median
2019 $37 $150 $41–$543 $163
2020 $0 $120 $32–$415 $114
2021 $0 $137 $35–$551 $132
2022 $12 $137 $37–$512 $149
2023 $570 $149 $42–$545 $160
2024 $149 $156 $44–$560 $164
2025 $385 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $205 10 payments
  2. Imperative Care, INc $102 1 payment
  3. Kerecis Limited $88 5 payments
  4. Exact Sciences Corporation $76 4 payments
  5. Novo Nordisk Inc $71 4 payments
  6. AstraZeneca Pharmaceuticals LP $55 4 payments
  7. Janssen Pharmaceuticals, Inc $51 3 payments
  8. Lilly USA, LLC $41 3 payments
  9. Organogenesis Inc. $35 2 payments
  10. Neurelis, Inc. $34 1 payment
  11. Other $395 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,153 60 payments
Products named General payments · program years 2019–2025
  1. COLLAGENASE SANTYL $114 5 payments
  2. PRODIGY CATHETER $102 1 payment
  3. GRAFIX PL $90 5 payments
  4. Kerecis SurgiClose Wound Care $88 5 payments
  5. Kerecis SurgiClose Wound Care $88 5 payments
  6. Kerecis SurgiClose Wound Care $88 5 payments
  7. Kerecis GraftGuide $88 5 payments
  8. Kerecis SurgiClose Wound Care $88 5 payments
  9. Cologuard Collection Kit $76 4 payments
  10. Ozempic $58 3 payments
  11. Other $745 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 75 drugs

Part D claims

3,486

Median for Family Practice: 1,826

Drug cost

$470,324

Median for Family Practice: $120,094

Branded share of claims

23.1%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 101 $73,371
Mounjaro Tirzepatide Brand 61 $67,849
Jardiance Empagliflozin Brand 71 $64,540
Ozempic Semaglutide Brand 49 $50,911
Trulicity Dulaglutide Brand 31 $49,428
Farxiga Dapagliflozin Propanediol Brand 39 $47,394
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 53 $45,550
Rybelsus Semaglutide Brand 17 $16,770
Xarelto Rivaroxaban Brand 13 $9,487
Repatha Syringe Evolocumab Brand 13 $9,338

The 10 drugs with the highest cost, of 75 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$36,430

Of which drugs: $5,477

Medicare patients

92

Average age 71

Services billed

580

39 women, 53 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 45%
Diabetes 37%
Ischemic heart disease 30%
Chronic kidney disease 24%
Depression 23%
COPD 16%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 13 13 $3,760
Vaccine for influenza for injection into muscle 90653 Office 18 18 $1,473

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

60 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record